What happened
The FDA cleared the IND for Biolojic Design's BD200, an AI-designed bispecific antibody-drug conjugate whose arms can bind either Trop2 or Nectin-4. A global phase 1 study is expected to start in the coming weeks.
Why it matters
The design aims to get around single-antigen ADCs losing effectiveness as tumors become heterogeneous, because the molecule can adjust to which antigens a tumor expresses.
Summaries like this, every morning.
BD200 is entering first-in-human testing at a point when single-antigen antibody-drug conjugates are running into the problem of tumor heterogeneity — tumors that no longer express one target consistently. The bispecific design, with each arm able to bind either Trop2 or Nectin-4, is Biolojic Design's attempt to address that variability. The FDA's clearance of the IND moves the molecule from preclinical work into a global phase 1 study expected to start in the coming weeks, making it an early clinical test of whether an AI-designed multibody holds up in patients.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Omaha companies, including Union Pacific with its 'Rita' tool and others using Copilot, shared how they are ad…
OpenAI agreed to acquire Odessia, an AI trip-planning engine that sits between travelers and booking platforms…
ServiceNow launched its Autonomous CRM Engine, which uses AI to analyze existing CRM setups and automate workf…
Merck raised its full-year 2026 revenue forecast to between €21.5bn and €21.9bn, up from €21.0bn to €21.8bn, a…
Nvidia fell 26% and AMD 15% over the past month, yet Nvidia trades at a significantly cheaper valuation, and i…
NHS England removed a list stating 137 hospital trusts were "live" with and "realising benefits" from Palantir…
